Efficacy of Ⅰb and Ⅱ stage cervical cancer treated by intensity-modulated radiotherapy after surgery
YANG Jian1,XU Xinming1, LIU Ying1,and XU Gang2
1. Department of Radiation Oncology,Cangzhou People’s Hospital,Cangzhou 061000,China; 2. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Radiotherapy, Peking University Cancer Hospital & Institute,Beijing 100142, China
Abstract：Objective To analyze the efficacy and treatment related toxicities for patients with Ⅰb and Ⅱ stage cervical cancer treated by Intensity Modulated Radiation Therapy (IMRT).Methods From January 2008 to February 2012,83 patients with stageⅠb-Ⅱ postoperative cervical cancer were retrospectively analyzed.The clinical target volume received a dose of 50 Gy/25 fractions in all patients.All patients were treated by IMRT and cisplatin-based chemotherapy for 2-4 cycles.Results Treatment was completed successfully in all patients. The follow-up rate was 100%. In all patients, the 3-year overall survival (OS) rate was 89.2％, with disease-free survival (DFS) rate of 83.1％ and pelevic local control (LC) rate of 85.5％. The 3-year OS rates were 50％ and 91％ for patients with adenocarcinoma and squamous carcinoma(χ2=9.65,P=0.002). The incidences of grade 1-2 rectal toxicity , urinary toxicity and myelosuppression were 10.34％,10.34％ and 58.62％. There were no grade 4 toxicities.Conclusions The postoperative cervical cancer patients with poor prognostic factors who undergo IMRT can achieve high overall survival rates,local control rates and tolerable toxicities.
杨健,许新明,刘颖,徐刚. Ⅰb和Ⅱ期宫颈癌术后调强放疗的疗效[J]. 武警医学, 2015, 26(10): 1001-1003.
YANG Jian,XU Xinming, LIU Ying,and XU Gang. Efficacy of Ⅰb and Ⅱ stage cervical cancer treated by intensity-modulated radiotherapy after surgery. Med. J. Chin. Peop. Armed Poli. Forc., 2015, 26(10): 1001-1003.
Cox J D, Stetz J, Pajak T F, et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) [J]. Int J Radiat Oncol Biol Phys, 1995,31(5):1341-1346.
[4]
Cox J D, Stetz J, Pajak T F, et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) [J]. Int J Radiat Oncol Biol Phys, 1995,31(5):1341-1346.
Rydzewska L, Tierney J, Vale C L, et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer[J]. Cochrane Database Syst Rev, 2012,12:CD007406.
[6]
Rydzewska L, Tierney J, Vale C L, et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer[J]. Cochrane Database Syst Rev, 2012,12:CD007406.
[7]
Biewenga P, van der Velden J, Mol B W, et al. Prognostic model for survival in patients with early stage cervical cancer[J]. Cancer, 2011,117(4):768-776.
[7]
Biewenga P, van der Velden J, Mol B W, et al. Prognostic model for survival in patients with early stage cervical cancer[J]. Cancer, 2011,117(4):768-776.
[8]
Pieterse Q D, Trimbos J B, Dijkman A, et al. Postoperative radiation therapy improves prognosis in patients with adverse risk factors in localized, early-stage cervical cancer: a retrospective comparative study[J]. Int J Gynecol Cancer, 2006,16(3):1112-1118.
[8]
Pieterse Q D, Trimbos J B, Dijkman A, et al. Postoperative radiation therapy improves prognosis in patients with adverse risk factors in localized, early-stage cervical cancer: a retrospective comparative study[J]. Int J Gynecol Cancer, 2006,16(3):1112-1118.
Van de Bunt L, Van der Heide UA, Ketelaars M, et al. Conventional, conformal, and intensity-modulated radiation therapy treatment planning of external beam radiotherapy for cervical cancer: The impact of tumor regression[J]. Int J Radiat Oncol Biol Phys, 2006,64(1):189-196
[10]
Van de Bunt L, Van der Heide UA, Ketelaars M, et al. Conventional, conformal, and intensity-modulated radiation therapy treatment planning of external beam radiotherapy for cervical cancer: The impact of tumor regression[J]. Int J Radiat Oncol Biol Phys, 2006,64(1):189-196
2015, Vol. 26 
